Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream
NCT ID: NCT01021787
Last Updated: 2011-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
26 participants
INTERVENTIONAL
2009-12-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
In Vivo Sun Protection Factor Determination
NCT02792595
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema
NCT05300542
Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
NCT03892564
Evaluate the Photoprotection Efficiency of Sunscreen Formulas Under Visible Light Exposure
NCT06796088
Evaluation of the Photoprotection Efficacy with Sunscreen Formulas Under Visible Light Exposure
NCT06803901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Titanium dioxide
Topical cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. be between the ages of 18 and 65.
2. agree to not participate in any other product evaluations or clinical evaluations during the course of this study.
3. have read, understood and signed an Informed Consent Form.
4. have intact skin in the treatment area.
5. have fair skin - Skin Types I, or II - as defined in Appendix II.
6. be able to understand and willing to follow all study procedures and restrictions.
Exclusion Criteria
1. are female and are pregnant or lactating \[must be using an acceptable method of birth control if of child bearing potential\].\*
2. exhibit any visible symptoms of skin disease, such as psoriasis or eczema, or skin abnormality (including active dermal lesions, uneven skin tone or scars) which might interfere with interpretation of the study results. The presence of nevi, blemishes, or moles will be acceptable if, in the Investigator's judgement, they will not interfere with the study results or skin stripping procedures.
3. have a history of allergic responses to sunscreens or other products similar to those included in this study.
4. have very dry or scaly skin on the test site.
5. have diabetes.
6. have a history of abnormal responses to sunlight, such as a phototoxic or photoallergic response.
7. have an existing sunburn or suntan, or been to a tanning booth which would interfere with interpretation of the study results.
8. have used self tanners within the past two weeks.
9. have excessive hair at the test site area which could, in the opinion of the investigator, interfere with the interpretation of the results.
10. have participated in a research drug trial or patch test within six weeks of beginning this study.
11. have a known sensitivity to Scotch 600 Transparent Tape.
12. are currently receiving, or within the past two weeks received, topical or systemic medication which could, in the opinion of the investigator, interfere with the interpretation of the results, affect the safety of the subject, or which may change the body's response to ultraviolet light.
13. are currently taking any of the drugs listed on the next page. In addition, the use of St. John's Wort or other similar dietary supplements, aspirin or OTC ibuprofen is contraindicated for the duration of the study. Low dose daily aspirin use, 81 mgs, taken for heart attack prevention is excluded.
* Acceptable methods of birth control that can be used during the course of the study are: oral contraceptive pill, intrauterine device, patch, injection, condom with spermicide, partner vasectomy, bilateral tubal ligation, abstinence or evidence of non childbearing potential (i.e., post-menopausal \[one year without menstrual period\], hysterectomy or bilateral ovariectomy).
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Loreal USA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
L'Oreal USA Products Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hill Top Research
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEN.750.06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.